Introduction: Chronic bronchitis is one of the common clinical problems seen in middle-older age group and occurs as a result of inflammation and swelling of the lining of the airways, leading to narrowing and obstruction generally resulting in persistent cough, associated with wheezing, chest pain, and shortness of breath. Chronic bronchitis can be symptomatically compared with Kasa Roga in Ayurveda.
INTRODUCTION
Chronic bronchitis is one of the most distressing diseases and is quite common in all the socioeconomic strata and is more common in middle-aged males than in females. Approximately 20% of adult males and 5% of adult women are affected. 1 Chronic bronchitis is defined as chronic cough and sputum production for at least 3 months a year for two consecutive years. 2 The hypersecretion of mucus is a result of hypertrophy of submucosal glands and increased numbers of goblet cells in the epithelium. Mucociliary clearance is delayed due to excess mucus production and loss of ciliated cells, and this leads to a history of productive cough. 3 The other identifying symptoms are chronic cough with expectoration, dyspnea, chest pain, wheezing, sore throat, and nasal congestion. If not treated it could lead to major outcomes, such as reduced lung function, impaired health status, reduced exercise capacity, frequent exacerbations, and possibly increased mortality. Cough with sputum is more noticeable in the morning because of pooling of nocturnal secretions in the supine position which are then mobilized with morning activities. Chronic upper respiratory disease of both allergic and infectious nature may be a commonly associated or precipitating factor. 4 The most frequent fatal consequence is acute exacerbation with respiratory failure in 50% cases with 10 years history of CB. Such acute exacerbations are often precipitated by bacterial infection. Chronic bronchitis can be symptomatically correlated with Kasa in Ayurveda. Kasa is a Vata-kaphaj vyadhi that occurs when obstructed Vyan Vayu travels upward in Pratiloma Gati and vitiates Udana Vayu propelling the air upward and out of the body. 5 It has its physical origin in the Purishavaha Srotas (large intestine) where accumulation and aggravation of the Dosha take place. At the initial stage of onset, it is said to be Sadhya (Curable) but in chronic and especially in old age it becomes Yapya (Manageable/controllable). 6 The contemporary treatment of bronchitis is only symptomatic, which includes bronchodilators, expectorants, steroids and artificial supply of oxygen, while in chronic conditions strengthening of the respiratory muscles, supplemental oxygen, hydration, and nutritional support are required. Several indigenous drugs have been successfully tested and used as conservative therapy in CB. The goal of CB treatment has shifted from symptom relief to disease control and it also ensures the patient's wellbeing. Herbal preparations have been cited as the third most popular complementary treatment modality. The medicine Vasavaleha 7, 8 is used since ages for various types of Kasa treatment but no validation study is completed till date, hence this study is carried out to evaluate the efficacy and safety of this compound formulation with clinical validation in the management of CB.
OBJECTIVES
To evaluate the efficacy and safety of Vasavaleha in patients suffering from stable CB.
MATERIALS AND METHODS

Study Design
The 
Inclusion Criteria
Patients of either sex aged between 16 and 70 years, with history of uncomplicated chronic bronchitis and who were willing to participate in the study for 14 weeks.
Exclusion Criteria
Patients suffering from acute bronchitis, patients having PEFR < 50% of the predicted value, presence of other pulmonary diseases like emphysema, cor pulmonale, cyanosis, pneumonia, asthma, cystic fibrosis, tuberculosis, lung cancer, etc., patients with uncontrolled diabetes mellitus (blood sugar fasting > 250 mg/dL), patients with poorly controlled hypertension [mean sitting blood pressure (BP) ≥160/100 mm Hg], patients on prolonged (>6 weeks) medication with corticosteroids, bronchodilators, mast cell stabilizers, antidepressants, anticholinergics, etc., or any other drugs that may have an influence on the outcome of the study. Patients suffering from major systemic illness necessitating longterm drug treatment (rheumatoid arthritis, tuberculosis, psycho-neuro-endocrinal disorders, etc.), patients who have a past history of atrial fibrillation, acute coronary syndrome, myocardial infarction, stroke, or severe arrhythmia in the last 6 months, symptomatic patients with clinical evidence of heart failure were excluded from the trial. Patients with concurrent serious hepatic disorder (defined as aspartate aminotransferase and/or alanine aminotransferase, total bilirubin, alkaline phosphatase >3 times upper normal limit) or renal disorders (defined as serum creatinine >1.2 mg/dL), alcoholics, and/or drug abusers, patients with history of hypersensitivity to the trial drug or any of its ingredients, patients who have completed participation in any other clinical trial during the past 6 months, pregnant or lactating women, and any other condition which the investigator thinks may jeopardize the study were also excluded from the study.
Study Interventions
The study medications including vasavaleha [14] in the dose of 10 gm twice daily were given with water for a period of 12 weeks. The formulation was procured from IMPCL, a government pharmacy as per pharmacopoeia standards, which was good manufacturing practice certified and it was standardized following the standards laid in Ayurvedic Pharmacopoeia of India. Patients were also guided regarding pathya-apathya and during their follow-up visits they were asked in details for their diet patterns.
Study Procedure
On the enrolment day at baseline (Visit 1), patient's demographic profile, family history, medical history, particularly related to PEFR, FEV1 in first second and SGRQ score. Subsequent visits were planned at an interval of 2 weeks [14th day (Visit 2), 28th day (Visit 3), 42nd day (Visit 4), 56th day (Visit 5), 70th day (Visit 6), and 84th day (Visit 7)]. Patients were assessed and given study medications at each subsequent visit till 84th day. There was also a without medication follow-up after 2 weeks of 84th day visit. Details of clinical assessment and study schedule are given in Flow Chart 1.
At the study site, data of all the patients were recorded in predesigned case report forms (CRFs) and was also entered in electronic formats (e-formats) designed in MS-Excel with many data validation checks to ensure correct data entry. The e-formats and Xerox of the CRFs along with the laboratory investigations reports of the patients were sent by the participating centers to the Council's headquarters on weekly basis for the purpose of clinical trial monitoring.
Out of the total 126 patients enrolled in the study, three dropped out during the course of the study. Imputation was applied on those three patients. Hence, data of a total 126 patients was used for statistical analysis. Flow Chart 2 shows the outflow of the patients in the study.
Outcomes
The primary outcome measures were change in the clinical symptoms of CB. The secondary outcome measures were change in SGRQ scores and any acute exacerbations of bronchitis occurring during the trial period.
Statistical Analysis
Clinical symptoms, subjective parameters, and laboratory parameters were subjected to univariate and multivariate analysis using Statistical Packages for the Social Sciences 15.0 version with appropriate statistical methods.
RESULTS
Data of 126 patients (67 males and 59 females) were used for statistical analysis, out of which maximum patients 37 (29.4%) were in the age group of 34 to 42 years; 86 (68.3%) patients were of pitta-kaphaja sharirik prakriti. Among total patients, 94 were married (74.6%). Number of literate patients who were able to read and write was 114 (90.5%). Table 1 . Mean systolic blood pressure was 121.29 and mean diastolic blood pressure was 77.48.
Significant effect of vasavaleha was seen on the common complaints faced by patients suffering from CB. The complaint of productive cough was observed in 126 patients at baseline and was found only in 93 patients at the end of treatment. Complaint of dyspnea reduced in 39.7% patients and wheezing was reduced in 21.4% patients. Likewise, complaint of chest pain, sore throat, and nasal congestion got reduced in 37.2, 64.3 and 57.2% patients respectively. The effect of the trial medication Vasavaleha on the complaints faced by patients of CB is shown in Table 2 . Table 2 shows the presence of symptoms in the patients at baseline, 84th day, and follow-up at the end of 14th week. The complaint of productive cough was present in all the patients enrolled at baseline, which on 84th day subsided in 33 (26.2%) of the patients and remained in 93 (73.8%) of the patients. It may be noted that chest pain was present in 58 (46.0%) patients at baseline which after treatment was reported in only 11 (8.8%) of the patients. That means, the symptom of chest pain improved in 81% of the patients [(58-11/58) × 100]. Similarly dyspnea was present in 77 (61.1%) of the patients at baseline, which on 84th day remained in only 27 (21.4%) of the patients. Therefore, the complaint of dyspnea had improved in 64.9% patients. Similarly significant improvement was also seen in the complaints of wheezing, nasal congestion, and sore throat. The complaint of sore throat was present in 108 (85.7%) of the patients at baseline, which improved significantly at 84th day and remained only in 27 (21.4%) of the patients. However, a mild increase in the presence of complaint of sore throat was observed at follow-up at the end of 14th week (without medicine follow-up) which was seen in 29 (23.0%) of the patients as compared with 27 (21.4%) patients at 84th day. However, the increase was not statistically significant.
Effect of the study medication was also assessed by paired t-test on PEFR (L/min) (Graph 1), FEV1 (L/min) (Graph 2), and SGRQ compared at baseline and at 84th
Flow Chart 2: Outflow of the patients in the study day. Table 3 shows the results of the analysis of those parameters. The study shows significant effect on the outcome parameters as the PEFR value increased from 351.69 (at the baseline) to the 417.37 (at the 84th day). Likewise, value of FEV1 was increased from 1.84 on the baseline to 2.05 at the 84th day. Also, significant results were found in all the domains of SGRQ, and total value decreased from 31.16 at the baseline to the 15.66 on 84th day.
Safety Profile
The effect of this treatment on various safety parameters, such as liver function tests and renal function tests, was assessed at baseline and at 84th day visit. The values were within limits during the entire trial period (Graphs 3 to 5). Table 4 shows the effect of the drugs on the safety parameters. No adverse reaction or adverse event was observed during the entire trial period.
DISCUSSION AND CONCLUSION
In CB, there is inflammation and swelling of the lining of the airways, leading to narrowing and obstruction generally resulting in daily cough. The inflammation stimulates production of mucus, which can cause further blockage of the airways. Chronic bronchitis can be symptomatically compared with kasa roga. Kasa originates by Pratiloma gati of Apana vayu due to sroto-avarodha which manifests through Pranavaha Srotas. Hence, the drugs which are having 9 Pippali is Vata-kaphaghna, bronchodilator, immuno-stimulator and antiinflammatory, 10 Sarpi is vatanulomana, vata-kaphaghna, Sharkara is anulomaka, honey is yogvahi. 11 Hence, the synergistic effect of these ingredients might help in relieving the subjective and objective parameters of Kasa (CB). Based on this multicenter clinical trial, it is inferred that Vasavaleha has good efficacy in the management of CB. This drug has shown significant improvement in all the clinical parameters, lung function tests, viz., PEFR, FEV1, and also SGRQ score. This drug can be safely used for the management of CB. This type of validation study on commonly used Ayurvedic formulations will be helpful in designing national health policies and globalization of the traditional system.
